|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||420.01 - 428.17|
|52-week range||370.22 - 475.44|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||22.54|
|Forward dividend & yield||2.80 (0.66%)|
|Ex-dividend date||29 Jun 2021|
|1y target est||N/A|
Humana's (HUM) second-quarter earnings gain from higher revenues and strong performances by its Retail and Healthcare Services segments.
Health insurer spending on medical claims fell during the height of the pandemic as patients and hospitals postponed non-urgent surgeries to soften the impact on the healthcare system, but benefits from deferred care were offset by higher spending on COVID-19 testing and treatment. "We do expect, given that the country has been largely open, our population is largely vaccinated, that we will see non-COVID utilization start to normalize," Chief Financial Officer Susan Diamond said. Humana said it has seen COVID-19 testing and treatment costs come down faster than initially expected in the first half of the year, but non-coronavirus outpatient costs were rebounding faster than anticipated.
Humana (HUM) delivered earnings and revenue surprises of 0.44% and 0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?